ロード中...

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy

Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In particular combinations with Decitabine and V...

詳細記述

保存先:
書誌詳細
出版年:Oncotarget
主要な著者: Young, Christine S., Clarke, Kathryn M., Kettyle, Laura M., Thompson, Alexander, Mills, Ken I.
フォーマット: Artigo
言語:Inglês
出版事項: Impact Journals LLC 2017
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584259/
https://ncbi.nlm.nih.gov/pubmed/28881658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18009
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!